Novartis, Amgen rack up their first PhIII success in a crowded CGRP migraine drug field
Novartis and its partners at Amgen say that their CGRP migraine drug erenumab (AMG 334) came through in a Phase III study, beating a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
